Skip Navigation



European Heart Journal Advance Access published online on April 3, 2008

European Heart Journal, doi:10.1093/eurheartj/ehn136
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/9/1168    most recent
ehn136v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Skurk, C.
Right arrow Articles by Poller, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skurk, C.
Right arrow Articles by Poller, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy

Carsten Skurk1,*, Frank Wittchen1, Lennart Suckau1, Henning Witt2,3, Michael Noutsias1, Henry Fechner1, Heinz-Peter Schultheiss1 and Wolfgang Poller1

1 Department of Cardiology and Pneumology, Campus Benjamin Franklin, Charité University Medicine Berlin, Hindenburgdamm 30, 12200 Berlin, Germany
2 Center for Cardiovascular Research, Charité University Medicine Berlin, Hessische Strasse 3–4, 10117 Berlin, Germany
3 Max Planck Institute for Molecular Genetics, Ihnestrasse 63-73, 14195 Berlin, Germany

Received 26 September 2007; revised 29 February 2008; accepted 10 March 2008.

* Corresponding author. Tel: +49 30 8445 2383, Fax: +49 30 8445 3565, Email: skurkc{at}yahoo.com

Aims: Despite recent advances in medical therapy, heart failure remains a leading cause for cardiovascular mortality, and its complex pathogenesis is incompletely understood. This study was performed to identify possible new therapeutic targets in dilated cardiomyopathy (DCM).

Methods and results: Oligonucleotide microarray analysis was performed on endomyocardialbiopsies (EMBs) from patients with early DCM (LVEDD ≥ 55 mm, LVEF ≤ 55%,n= 5) and control subjects (LVEDD < 55 mm, LVEF > 60%, no cardiac pathology,n= 4). Adiponectin, an adipocytokine involved in cellular metabolism, survival, and immunmodulation, was six-fold downregulated in DCM patients. Microarray data for adiponectin were confirmed by TaqMan-PCR (9.2-fold downregulation, control n= 9 vs. DCM n= 9, respectively, P < 0.05). Immunohistological analysis of EMBs showed significant downregulation of cardiac adiponectin protein expression independent of serum adiponectin (P = 0.36, ns) or serum TNF{alpha} concentrations (P = 0.46, ns). Neither the adiponectin receptor 1 (adipo-R1) nor adipo-R2 was deregulated in early DCM. Adiponectin mRNA and protein downregulation were confirmed in explanted hearts of patients with advanced DCM (LVEF < 25%, n= 8). In vitro, adiponectin incubation of neonatal rat ventricular myocytes led to activation of the pro-survival kinase PKB/Akt, increased eNOS-phosphorylation, and prevented stress-induced apoptosis of cardiomyocytes in an Akt-dependent manner. Moreover, inhibition of adiponectin secretion was accompanied by an increase in the expression of the cytokine and its receptors.

Conclusion: These data indicate the existence of a local cardiac adiponectin system regulated independent of adiponectin and TNF{alpha} serum levels and its disturbance in cardiac pathology. The study suggests a role for adiponectin in the pathogenesis of DCM and implicates the adipocytokine as a possible future therapeutic target in DCM.

Key Words: Dilated cardiomyopathy • Adiponectin • Adiponectin receptors • Heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
A. Kis, C. Murdoch, M. Zhang, A. Siva, S. Rodriguez-Cuenca, S. Carobbio, A. Lukasik, M. Blount, S. O'Rahilly, S. L. Gray, et al.
Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice
Eur J Heart Fail, June 1, 2009; 11(6): 533 - 541.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.